Maralixibat

(Livmarli®)

Livmarli®

Drug updated on 11/15/2023

Dosage FormOral solution (oral; 9.5 mg/mL)
Drug ClassIleal bile acid transporter inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Livmarli (maralixibat) Prescribing Information.2023Mirum Pharmaceuticals Inc., Foster City, CA

Systematic Reviews / Meta-Analyses